San Francisco, United States
T-knife Therapeutics is a biopharmaceutical innovator founded in 2018 in the United States. The company is at the forefront of developing transformative therapies to combat cancer through its proprietary technology. Central to its mission is a paradigm-shifting approach utilizing its HuTCR mouse platform, designed to create human TCRs tailored for cancer treatment, identical to its mantra: "T-knife uses a mouse platform to create human TCRs for cancer treatment without modification."
The company is capitalizing on the potential of T cell receptor (TCR) engineered T cells, focusing on TCR-T therapies potentially pivotal for treating solid tumors. Targeting antigens like cancer testis and oncoviral antigens reflects their commitment to addressing high unmet medical needs.
The company’s last financial milestone was a hefty $110.00M Series B investment secured in August 2021, with backing from renowned investors like Casdin Capital and RA Capital Management. These investments spotlight T-knife's promising trajectory and investor confidence in their innovative roadmap.
